Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 6/20 | 0.68 |
| ▸ | NPY2R | P49146 | 8/20 | 0.67 |
| ▸ | NPY4R | P50391 | 8/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.67 |
| ▸ | NPY1R | P25929 | 6/20 | 0.67 |
| ▸ | KDM1A | O60341 | 2/20 | 0.64 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.63 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | KDM5A | P29375 | 1/20 | 0.62 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533701 | 1.00 | TFPI (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29629341 | 1.00 | TFPI (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29973299 | 0.99 | TFPI (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30017187 | 0.92 | NPY2R (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31121841 | 0.92 | NMUR2 (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29625796 | 0.91 | KDM1A (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30176437 | 0.91 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30176414 | 0.91 | TFPI (0.64) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30432104 | 0.91 | TFPI (0.69) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29625797 | 0.91 | TFPI (0.66) | TFPINPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250336657-A1 | Calibration Method, Analysis Method, Controller, and Analyzer | SHIMADZU CORP (JP) | 2025-10-30 | — | — | US | claimed |
| WO-2024005121-A1 | CALIBRATION METHOD, ANALYSIS METHOD, CONTROL DEVICE, AND ANALYSIS DEVICE | 株式会社島津製作所 | 2024-01-04 | — | — | WO | claimed |
| US-12595498-B2 | Method for producing cellooligosaccharide | DKS CO. LTD. (JP) | 2026-04-07 | — | — | US | disclosed |
| EP-4679097-A1 | METHOD FOR ESTIMATING BRAIN NEURODEGENERATIVE CONDITION | SHIMADZU CORPORATION (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-4679096-A1 | BIOMARKERS AND METHOD FOR ESTIMATING BRAIN NEURODEGENERATIVE CONDITION | SHIMADZU CORPORATION (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-12498380-B2 | Analysis method, peptide antioxidizing agent for use in MAKK spectrometry and kit for use in mass spectrometry | SHIMADZU CORPORATION (JP) | 2025-12-16 | — | — | US | disclosed |
| US-12463026-B2 | Machine difference correction method for mass spectrometry apparatus | SHIMADZU CORPORATION (JP) | 2025-11-04 | — | — | US | disclosed |
| US-12461092-B2 | Screening method for APP cleavage activity-controlling substances of ADAMTS4 | SHIMADZU CORPORATION (JP) | 2025-11-04 | — | — | US | disclosed |
| US-20250333488-A1 | PEPTIDE-HINGE-FREE FLEXIBLE ANTIBODY-LIKE MOLECULE | BIOMOLECULAR HOLDINGS LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250334583-A1 | METHOD FOR PREPARING SAMPLE SOLUTION CONTAINING NEUROGRANIN-RELATED PEPTIDE AND METHOD FOR ANALYZING NEUROGRANIN-RELATED PEPTIDE | SHIMADZU CORP (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20250336657-A1 | Calibration Method, Analysis Method, Controller, and Analyzer | SHIMADZU CORP (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20220268789-A1 | MONOCLONAL ANTIBODY AGAINST AMYLOID BETA, AND METHOD FOR MEASURING AMYLOID BETA-RELATED PEPTIDE USING SAID ANTIBODY | SHIMADZU CORPORATION (JP) | 2022-08-25 | — | — | US | disclosed |
| WO-2022176612-A1 | CALIBRANT FOR USE IN MASS SPECTROMETER AND METHOD FOR PRODUCING SAME | 株式会社 島津製作所 | 2022-08-25 | — | — | WO | disclosed |
| WO-2022168417-A1 | ANALYSIS METHOD | 株式会社島津製作所 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022153771-A1 | METHOD FOR PRODUCING CELLOOLIGOSACCHARIDE | 第一工業製薬株式会社 | 2022-07-21 | — | — | WO | disclosed |
| US-11345745-B2 | Peptide-hinge-free flexible antibody-like molecule | BIOMOLECULAR HOLDINGS LLC (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3995505-A1 | MONOCLONAL ANTIBODY AGAINST AMYLOID BETA, AND METHOD FOR MEASURING AMYLOID BETA-RELATED PEPTIDE USING SAID ANTIBODY | Shimadzu Corporation (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-11313862-B2 | Method for diagnosing amyotrophic lateral sclerosis using signal peptide as indicator | TOAGOSEI CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-11299555-B2 | Method for diagnosing alzheimer's disease using signal peptide as indicator | TOAGOSEI CO., LTD (JP) | 2022-04-12 | — | — | US | disclosed |
| US-11268965-B2 | Multiplex biomarker for use in evaluation of state of accumulation of amyloid B in brain, and analysis method for said evaluation | SHIMADZU CORPORATION (JP) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595498-B2 | Method for producing cellooligosaccharide | MGAM, PYGM, PMM2 | TFPI 3472/4885NPY2R 3919/4885NPY4R 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.